Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening

Iva Navratilova (Lead / Corresponding author), Tonia Aristotelous, Sarah Picaud, Apirat Chaikuad, Stefan Knapp, Panagis Filappakopoulos, Andrew L. Hopkins

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


The discovery of novel bromodomain inhibitors by fragment screening is complicated by the presence of dimethyl sulfoxide (DMSO), an acetyl-lysine mimetic, that can compromise the detection of low affinity fragments. We demonstrate surface plasmon resonance as a primary fragment screening approach for the discovery of novel bromodomain scaffolds, by describing a protocol to overcome the DMSO interference issue. We describe the discovery of several novel small molecules scaffolds that inhibit the bromodomains PCAF, BRD4, and CREBBP, representing canonical members of three out of the seven subfamilies of bromodomains. High-resolution crystal structures of the complexes of key fragments binding to BRD4(1), CREBBP, and PCAF were determined to provide binding mode data to aid the development of potent and selective inhibitors of PCAF, CREBBP, and BRD4.

Original languageEnglish
Pages (from-to)1213-1218
Number of pages6
JournalACS Medicinal Chemistry Letters
Issue number12
Early online date20 Sept 2016
Publication statusPublished - 8 Dec 2016


  • BRD4
  • Bromodomains
  • fragment screening
  • PCAF
  • surface plasmon resonance

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening'. Together they form a unique fingerprint.

Cite this